{"nctId":"NCT00321620","briefTitle":"Study of Denosumab vs. Zoledronic Acid to Treat Bone Metastases in Men With Hormone-refractory Prostate Cancer","startDateStruct":{"date":"2006-04-01","type":"ACTUAL"},"conditions":["Bone Metastases"],"count":1904,"armGroups":[{"label":"zoledronic acid","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: zoledronic acid"]},{"label":"denosumab","type":"EXPERIMENTAL","interventionNames":["Biological: denosumab"]}],"interventions":[{"name":"zoledronic acid","otherNames":["Zometa"]},{"name":"denosumab","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men \\>/= 18 years of age with histologically confirmed prostate cancer\n* Radiographic evidence of at least one bone metastasis\n* Failure of at least one hormonal therapy as evidenced by a rising PSA\n* Serum testosterone level of \\<50 ng/dL\n* ECOG PS 0, 1, or 2\n* Adequate organ function\n\nExclusion Criteria:\n\n* Current or prior IV bisphosphonate administration\n* Current or prior oral bisphosphonates for bone mets\n* Life expectancy of less than 6 months","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Time to the First On-Study SRE (Non-inferiority)","description":"Time to the first on-study skeletal-related event (SRE) analyzed for non-inferiority. Kaplan-Meier estimates of the median and its dispersion are reported.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"521.0","spread":null},{"groupId":"OG001","value":"629.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to the First On-Study SRE (Superiority)","description":"Time to the first on-study skeletal-related event (SRE), analyzed for superiority of denosumab. Kaplan-Meier estimates of the median and its dispersion are reported.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"521.0","spread":null},{"groupId":"OG001","value":"629.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to the First-And-Subsequent On-Study SRE","description":"Time to the first-and-subsequent on-study skeletal-related event (SRE), analyzed for superiority of denosumab using multiple event analysis, the event must occur at least 21 days after the previous SRE.\n\nThis outcome measure utilizes multiple event times, was analyzed based on a proportional mean model, and is therefore more appropriately summarized by the cumulative mean number of events.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"584","spread":null},{"groupId":"OG001","value":"494","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":568,"n":945},"commonTop":["Anaemia","Back pain","Decreased appetite","Nausea","Constipation"]}}}